258 related articles for article (PubMed ID: 34043813)
1. Decision fatigue in low-value prostate cancer screening.
Hunt TC; Ambrose JP; Haaland B; Kawamoto K; Dechet CB; Lowrance WT; Hanson HA; O'Neil BB
Cancer; 2021 Sep; 127(18):3343-3353. PubMed ID: 34043813
[TBL] [Abstract][Full Text] [Related]
2. Shared decision making in prostate-specific antigen testing: the effect of a mailed patient flyer prior to an annual exam.
Landrey AR; Matlock DD; Andrews L; Bronsert M; Denberg T
J Prim Care Community Health; 2013 Jan; 4(1):67-74. PubMed ID: 23799692
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer.
Hayat Roshanai A; Nordin K; Berglund G
Acta Oncol; 2013 Nov; 52(8):1602-8. PubMed ID: 23421929
[TBL] [Abstract][Full Text] [Related]
4. Disparities Associated with Shared Decision-making in Prostate Cancer Screening.
Basin MF; Crane K; Basnet A; Chandrasekar T; Shapiro O; Jacob JM; Bratslavsky G; Goldberg H
Eur Urol Focus; 2023 Nov; 9(6):1008-1015. PubMed ID: 37198068
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen testing among the elderly in community-based family medicine practices.
Hudson SV; Ohman-Strickland P; Ferrante JM; Lu-Yao G; Orzano AJ; Crabtree BF
J Am Board Fam Med; 2009; 22(3):257-65. PubMed ID: 19429731
[TBL] [Abstract][Full Text] [Related]
6. Clinicians' perceptions of the benefits and harms of prostate and colorectal cancer screening.
Elstad EA; Sutkowi-Hemstreet A; Sheridan SL; Vu M; Harris R; Reyna VF; Rini C; Earp JA; Brewer NT
Med Decis Making; 2015 May; 35(4):467-76. PubMed ID: 25637592
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
8. "Shared decision-making" for prostate cancer screening: Is it a marker of quality preventative healthcare?
Golijanin B; Bhatt V; Homer A; Malshy K; Ochsner A; Wales R; Khaleel S; Mega A; Pareek G; Hyams E
Cancer Epidemiol; 2024 Feb; 88():102492. PubMed ID: 38056246
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with appropriate and low-value PSA testing.
Oswald N; Lin T; Haaland B; Flynn M; Kawamoto K; Cooney KA; Lowrance W; Hanson HA; O'Neil B
Cancer Epidemiol; 2020 Jun; 66():101724. PubMed ID: 32361642
[TBL] [Abstract][Full Text] [Related]
10. Clinician interest in clinical decision support for PSA-based prostate cancer screening.
Harper J; Hunt T; Choudry M; Kapron AL; Cooney KA; Martin C; Ambrose J; O'Neil B
Urol Oncol; 2023 Mar; 41(3):145.e17-145.e23. PubMed ID: 36610816
[TBL] [Abstract][Full Text] [Related]
11. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
Bunting PS; Goel V; Williams JI; Iscoe NA
CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
[TBL] [Abstract][Full Text] [Related]
13. National evidence on the use of shared decision making in prostate-specific antigen screening.
Han PK; Kobrin S; Breen N; Joseph DA; Li J; Frosch DL; Klabunde CN
Ann Fam Med; 2013; 11(4):306-14. PubMed ID: 23835816
[TBL] [Abstract][Full Text] [Related]
14. A patient recall program to enhance decisions about prostate cancer screening: a feasibility study.
Denberg TD; Bhide M; Soenksen A; Mizrahi T; Shields L; Lin CT
BMC Fam Pract; 2009 Nov; 10():75. PubMed ID: 19948028
[TBL] [Abstract][Full Text] [Related]
15. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
Zanwar P; Lin YL; Kuo YF; Goodwin JS
BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
[TBL] [Abstract][Full Text] [Related]
16. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
17. Does shared decision making increase prostate screening uptake in countries with a low prevalence of prostate cancer?
Amin HS; Arafa MA; Farhat KH; Rabah DM; Altaweel AA; Alhammad AH
Afr Health Sci; 2020 Dec; 20(4):1870-1874. PubMed ID: 34394251
[TBL] [Abstract][Full Text] [Related]
18. Recent Patterns in Shared Decision Making for Prostate-Specific Antigen Testing in the United States.
Fedewa SA; Gansler T; Smith R; Sauer AG; Wender R; Brawley OW; Jemal A
Ann Fam Med; 2018 Mar; 16(2):139-144. PubMed ID: 29531105
[TBL] [Abstract][Full Text] [Related]
19. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending.
Kim DD; Daly AT; Koethe BC; Fendrick AM; Ollendorf DA; Wong JB; Neumann PJ
JAMA Netw Open; 2022 Nov; 5(11):e2243449. PubMed ID: 36413364
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Receipt of Information on Prostate-Specific Antigen Testing on Screening with the Prostate-Specific Antigen Test.
McCormick ME; Haile ZT
J Cancer Educ; 2023 Aug; 38(4):1313-1321. PubMed ID: 36652189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
